174 related articles for article (PubMed ID: 17693582)
1. Adaptor protein Lnk negatively regulates the mutant MPL, MPLW515L associated with myeloproliferative disorders.
Gery S; Gueller S; Chumakova K; Kawamata N; Liu L; Koeffler HP
Blood; 2007 Nov; 110(9):3360-4. PubMed ID: 17693582
[TBL] [Abstract][Full Text] [Related]
2. Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F.
Gery S; Cao Q; Gueller S; Xing H; Tefferi A; Koeffler HP
J Leukoc Biol; 2009 Jun; 85(6):957-65. PubMed ID: 19293402
[TBL] [Abstract][Full Text] [Related]
3. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
4. Lnk inhibits Tpo-mpl signaling and Tpo-mediated megakaryocytopoiesis.
Tong W; Lodish HF
J Exp Med; 2004 Sep; 200(5):569-80. PubMed ID: 15337790
[TBL] [Abstract][Full Text] [Related]
5. Expression level and differential JAK2-V617F-binding of the adaptor protein Lnk regulates JAK2-mediated signals in myeloproliferative neoplasms.
Baran-Marszak F; Magdoud H; Desterke C; Alvarado A; Roger C; Harel S; Mazoyer E; Cassinat B; Chevret S; Tonetti C; Giraudier S; Fenaux P; Cymbalista F; Varin-Blank N; Le Bousse-Kerdilès MC; Kiladjian JJ; Velazquez L
Blood; 2010 Dec; 116(26):5961-71. PubMed ID: 20870899
[TBL] [Abstract][Full Text] [Related]
6. Lnk controls mouse hematopoietic stem cell self-renewal and quiescence through direct interactions with JAK2.
Bersenev A; Wu C; Balcerek J; Tong W
J Clin Invest; 2008 Aug; 118(8):2832-44. PubMed ID: 18618018
[TBL] [Abstract][Full Text] [Related]
7. Lnk inhibits erythropoiesis and Epo-dependent JAK2 activation and downstream signaling pathways.
Tong W; Zhang J; Lodish HF
Blood; 2005 Jun; 105(12):4604-12. PubMed ID: 15705783
[TBL] [Abstract][Full Text] [Related]
8. LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations.
Pardanani A; Lasho T; Finke C; Oh ST; Gotlib J; Tefferi A
Leukemia; 2010 Oct; 24(10):1713-8. PubMed ID: 20724988
[TBL] [Abstract][Full Text] [Related]
9. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
10. Lnk adaptor protein down-regulates specific Kit-induced signaling pathways in primary mast cells.
Simon C; Dondi E; Chaix A; de Sepulveda P; Kubiseski TJ; Varin-Blank N; Velazquez L
Blood; 2008 Nov; 112(10):4039-47. PubMed ID: 18753636
[TBL] [Abstract][Full Text] [Related]
11. LNK mutations and myeloproliferative disorders.
McMullin MF; Cario H
Am J Hematol; 2016 Feb; 91(2):248-51. PubMed ID: 26660394
[TBL] [Abstract][Full Text] [Related]
12. Adaptor protein Lnk binds to PDGF receptor and inhibits PDGF-dependent signaling.
Gueller S; Hehn S; Nowak V; Gery S; Serve H; Brandts CH; Koeffler HP
Exp Hematol; 2011 May; 39(5):591-600. PubMed ID: 21310211
[TBL] [Abstract][Full Text] [Related]
13. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.
Oh ST; Simonds EF; Jones C; Hale MB; Goltsev Y; Gibbs KD; Merker JD; Zehnder JL; Nolan GP; Gotlib J
Blood; 2010 Aug; 116(6):988-92. PubMed ID: 20404132
[TBL] [Abstract][Full Text] [Related]
14. Expression of the adaptor protein Lnk in leukemia cells.
Gery S; Gueller S; Nowak V; Sohn J; Hofmann WK; Koeffler HP
Exp Hematol; 2009 May; 37(5):585-592.e2. PubMed ID: 19375649
[TBL] [Abstract][Full Text] [Related]
15. Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.
Looi CY; Imanishi M; Takaki S; Sato M; Chiba N; Sasahara Y; Futaki S; Tsuchiya S; Kumaki S
PLoS One; 2011; 6(8):e23640. PubMed ID: 21853157
[TBL] [Abstract][Full Text] [Related]
16. Defining the requirements for the pathogenic interaction between mutant calreticulin and MPL in MPN.
Elf S; Abdelfattah NS; Baral AJ; Beeson D; Rivera JF; Ko A; Florescu N; Birrane G; Chen E; Mullally A
Blood; 2018 Feb; 131(7):782-786. PubMed ID: 29288169
[TBL] [Abstract][Full Text] [Related]
17. A novel MPL point mutation resulting in thrombopoietin-independent activation.
Abe M; Suzuki K; Inagaki O; Sassa S; Shikama H
Leukemia; 2002 Aug; 16(8):1500-6. PubMed ID: 12145691
[TBL] [Abstract][Full Text] [Related]
18. Lnk adaptor suppresses radiation resistance and radiation-induced B-cell malignancies by inhibiting IL-11 signaling.
Louria-Hayon I; Frelin C; Ruston J; Gish G; Jin J; Kofler MM; Lambert JP; Adissu HA; Milyavsky M; Herrington R; Minden MD; Dick JE; Gingras AC; Iscove NN; Pawson T
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20599-604. PubMed ID: 24297922
[TBL] [Abstract][Full Text] [Related]
19. 14-3-3 regulates the LNK/JAK2 pathway in mouse hematopoietic stem and progenitor cells.
Jiang J; Balcerek J; Rozenova K; Cheng Y; Bersenev A; Wu C; Song Y; Tong W
J Clin Invest; 2012 Jun; 122(6):2079-91. PubMed ID: 22546852
[TBL] [Abstract][Full Text] [Related]
20. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets.
Glembotsky AC; Korin L; Lev PR; Chazarreta CD; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2010 May; 84(5):398-405. PubMed ID: 20113333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
